Aratana Therapeutics (NASDAQ:PETX) Upgraded by Zacks Investment Research to Hold

Zacks Investment Research upgraded shares of Aratana Therapeutics (NASDAQ:PETX) from a sell rating to a hold rating in a research report report published on Wednesday, Zacks.com reports.

According to Zacks, “Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas. “

A number of other equities analysts have also recently commented on the stock. Credit Suisse Group raised shares of ConocoPhillips from a neutral rating to an outperform rating and set a $75.00 price target for the company in a research note on Tuesday, April 30th. HC Wainwright reissued a buy rating on shares of Oragenics in a research note on Friday, April 26th. Finally, BidaskClub raised shares of Zebra Technologies from a hold rating to a buy rating in a research note on Saturday, July 6th. One equities research analyst has rated the stock with a sell rating and six have given a hold rating to the company. The stock presently has an average rating of Hold and a consensus price target of $5.08.



Aratana Therapeutics stock traded up $0.07 during midday trading on Wednesday, reaching $5.06. 204,100 shares of the stock were exchanged, compared to its average volume of 789,433. The firm has a fifty day simple moving average of $4.93. The stock has a market cap of $244.36 million, a price-to-earnings ratio of -15.81 and a beta of 1.40. Aratana Therapeutics has a 52 week low of $3.30 and a 52 week high of $7.16.

Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.04). Aratana Therapeutics had a negative return on equity of 12.99% and a negative net margin of 33.47%. The company had revenue of $7.36 million during the quarter, compared to analysts’ expectations of $6.98 million. As a group, analysts anticipate that Aratana Therapeutics will post -0.31 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in PETX. Millennium Management LLC boosted its stake in shares of Aratana Therapeutics by 116.7% in the 4th quarter. Millennium Management LLC now owns 642,923 shares of the biopharmaceutical company’s stock valued at $3,941,000 after purchasing an additional 346,243 shares in the last quarter. Acadian Asset Management LLC boosted its stake in shares of Aratana Therapeutics by 83.7% in the 1st quarter. Acadian Asset Management LLC now owns 439,767 shares of the biopharmaceutical company’s stock valued at $1,583,000 after purchasing an additional 200,379 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Aratana Therapeutics by 5.5% in the 4th quarter. BlackRock Inc. now owns 3,629,595 shares of the biopharmaceutical company’s stock valued at $22,249,000 after purchasing an additional 190,011 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Aratana Therapeutics by 10.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,233,219 shares of the biopharmaceutical company’s stock valued at $7,559,000 after purchasing an additional 114,383 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Aratana Therapeutics by 21.2% in the 4th quarter. Geode Capital Management LLC now owns 526,329 shares of the biopharmaceutical company’s stock valued at $3,226,000 after purchasing an additional 91,968 shares in the last quarter. 65.00% of the stock is owned by institutional investors and hedge funds.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Its product portfolio includes small molecule therapeutics and therapeutic candidates. The company markets NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs; ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States.

Further Reading: What is the price-sales ratio?

Get a free copy of the Zacks research report on Aratana Therapeutics (PETX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.